Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' to the study's keywords.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check27 days agoChange DetectedNo additions or deletions are observed between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.0%

- Check34 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3, representing a minor metadata update.SummaryDifference0.0%

- Check55 days agoChange DetectedThe changes consist of an internal software revision update from v3.4.1 to v3.4.2; no content related to the study details, eligibility, or results appears to be altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor metadata change with no impact on the study details or functionality.SummaryDifference0.0%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.